SABRINA THALITA DOS REIS FARIA
Projetos de Pesquisa
Unidades Organizacionais
LIM/55 - Laboratório de Urologia, Hospital das Clínicas, Faculdade de Medicina - Líder
8 resultados
Resultados de Busca
Agora exibindo 1 - 8 de 8
conferenceObject DO THE REGULATION OF MATRIX METALLOPROTEINASES AND TISSUE INHIBITORS OF MATRIX METALLOPROTEINASES HAVE ANY ASSOCIATION WITH PEYRONIE'S DISEASE?(2020) NETO, Cristovao Barbosa; REIS, Sabrina T.; ARANTES, Gabriel; NASCIMENTO, Bruno; SAYAO, Rogerio; LEITE, Katia Ramos; SROUGI, Miguel; NAHAS, William; CURY, Jose- Nomograms using a small panel of genes for predicting the diagnosis and aggressiveness of prostate cancer(2020) LEITE, Katia R. M.; ORTEGA, Fabio L.; DAMIANI, Lucas P.; GUIMARAES, Vanessa; VIANA, Nayara; SILVA, Iran A.; REIS, Sabrina T.; PIMENTA, Ruan; ADONIAS, Sanarelly P.; CHAMMAS, Cristina; SROUGI, Miguel; NAHAS, Willian
- Indoleamine 2,3-dioxygenase expression in the prognosis of the localized prostate cancer(2020) FERREIRA, Janaina Mendes; DELLE, Humberto; CAMACHO, Cleber Pinto; ALMEIDA, Robson Jose; REIS, Sabrina Thalita; MATOS, Yves Silva Teles; LIMA, Amanda M. Ramos; LEITE, Katia Ramos Moreira; PONTES-JUNIOR, Jose; SROUGI, MiguelBackground Indoleamine 2,3-dioxygenase (IDO1) is an enzyme that acts as an immunomodulatory molecule. It is found in several types of cancer where it seems to be associated with tumor escape due to its immunosuppressive mechanisms. However, the role of IDO1 expression in prostate cancer (PC) is unclear. The aim of our study was to evaluate the expression of IDO1 in localized PC and to correlate with the classic prognostic factor and recurrence after surgical treatment. Methods We retrospectively evaluated surgical specimens from 111 patients with localized PC, who underwent radical prostatectomy. Recurrence was defined as a prostate specific antigen (PSA) level exceeding 0.2 ng/mL postoperatively, and the follow-up was 123 months. IDO1 expression was evaluated by immunohistochemistry in 72 cases of which 42 (58%) had biochemical recurrence. Results Lower IDO1 expression was associated with higher Gleason score (p = 0.022) and PSA levels (p = 0.042). The multivariate analyses revealed that the loss of IDO1 and higher PSA were independently associated with biochemical recurrence. The chance of recurrence was increased by 85% in patients with lower IDO1 [OR = 0.15;p = 0.009 CI 95% (0.038-0.633)] and increased by 5.5 times in patients with higher PSA [OR = 5.51;p = 0.012 CI 95% (1.435-21.21)]. The recurrence-free survival curve also demonstrates that lower IDO1 was associated with lower time to biochemical recurrence (p = 0.0004). Conclusion The loss of IDO1 expression was associated with increased chance of biochemical recurrence, higher PSA, and a Gleason score in localized PC.
- Digital application developed to evaluate functional results following robot-assisted radical prostatectomy* App for prostate cancer(2020) FARIA, Leandro F.; REIS, Sabrina T.; LEITE, Katia R.; CRUZ, Jose Arnaldo Shiomi da; PIMENTA, Ruan; I, Nayara Viana; AMARAL, Gabriela Q.; SANTOS, Gabriel A. G. D.; ILIAS, Daniel; FAKHOURI, Felipe; XAVIER, Geraldo; SROUGI, Miguel; PASSEROTTI, Carlo CamargoIntroduction: Mobile applications (""apps"") developed for smartphones and tablets are increasingly used in healthcare, allowing remote patient support or promoting self-health care. Prostate cancer (PC) screening allows for early-stage PC diagnosis, resulting in high rates of curative procedures such as radical prostatectomy. The main complications following surgery are urinary incontinence and erectile dysfunction. However, the exact numbers related to these morbidities are often missing due to brief interviews during consultations in the medical office. Therefore, the aim of this study was to create an app to determine whether response rates to preand post-surgical PC questionnaires will increase. Methods: The app was built using the IONIC framework system and provided to patients through a prospective randomized study. We included 100 patients divided into two groups: 1. first group used the app (n = 50); and 2. second group responded via validated printed questionnaires (control group) (n = 50). All patients received discharge counseling to respond to the questionnaires 1, 3, 6 and 12 months after the procedure. The app group received verbal guidance on how monitoring would occur, received an SMS containing a username and password providing access to the system and received reminder alerts to respond to the questionnaires. Results: The new app is called UroHealth and is available for download in the Apple App Store or at www.urohealth.com.br . When we evaluated the response rates, we found that 42.9% of the patients answered the preoperative questionnaire in the app group, while 16% responded in the control group (p = 0.003). By the end of the follow-up, we found that 24.5% of the patients answered the questionnaire in the app group, while 4% responded in the control group (p = 0.003). Conclusion: This app enabled almost 6 times more patients to answer long-term follow-up questions after surgical procedures, providing high-quality information regarding morbidity related to treatment. Although our initial results indicate that this app may become a useful tool in obtaining more frequent and realistic answers, thus helping to improve surgical techniques, other ways of reaching the patient should be tested to achieve higher response rates.
- Urinary biomarkers of inflammation and tissue remodeling may predict bladder dysfunction in patients with benign prostatic hyperplasia(2020) CONTI, Paulo Sajovic de; BARBOSA, Joao Arthur Brunhara Alves; REIS, Sabrina Thalita; I, Nayara Viana; GOMES, Cristiano Mendes; BORGES, Leonardo; NUNES, Marco; NAHAS, William C.; SROUGI, Miguel; ANTUNES, Alberto AzoubelPurpose To evaluate the expression of urinary biomarkers of inflammation and tissue remodeling in patients with BPH undergoing surgery and evaluate the association of biomarkers with postoperative urodynamic outcomes Materials and methods We analyzed urine samples from 71 patients treated with TURP from 2011 to 2017. Urinary levels of epidermal growth factor (EGF), matrix-metalloproteinase-1 (MMP-1), interleukin-6 (IL-6), nerve growth factor (NGF) and monocyte-chemoattractant protein-1 (MCP-1) (by commercial ELISA kit) were measured, adjusted by urinary creatinine (Cr) and analyzed according to patients clinical and urodynamic characteristics (baseline and 12-month postoperative urodynamic) Results MMP-1/Cr levels were significantly higher among subjects with higher detrusor pressure on preoprative urodynamic. MCP-1/Cr levels were significantly higher amongs subjects with preoperative DO. Preoperative levels of NGF/Cr (0.13 vs 0.08,p = 0.005) and MMP-1/Cr (0.11 vs 0.04,p = 0.021) were predictors of persistent DO 12 months after surgery. The following factors were shown to be useful for predicting the persistence of DO in the postoperative period: NGF/Cr, with an AUC of 0.77 (95% CI 0.62-0.92) (p = 0.006), and MMP-1/Cr, with an AUC of 0.72 (95% CI 0.56-0.88) (p = 0.022). Conclusions MMP-1/Cr was associated with higher detrusor pressure and MCP-1/CR with DO. NGF/Cr and MMP-1/Cr were shown to be predictors of persistent postoperative DO.
conferenceObject ANALYS MICRORNAS EXPRESSION IN CYSTINURIA PATIENTS(2020) AYRES, Daniel; SANTOS, Gabriel; PIMENTA, Ruan; VIANA, Nayara; GUIMARAES, Vanessa; SILVA, Iran; MARCHINI, Giovanni; BATAGELLO, Carlos; TORRICELLI, Fabio; VICENTINI, Fabio; DANILOVIC, Alexandre; LEITE, Katia; REIS, Sabrina; NAHAS, William; SROUGI, Miguel; MAZZUCCHI, EduardoconferenceObject DETRUSOR PRESSURES ARE ASSOCIATED WITH COLLAGEN TYPE III EXPRESSION IN THE DETRUSOR OF PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA(2020) BELLUCCI, Carlos; HEMERLY, Thiago; GUIMARAES, Vanessa; VIANA, Nayara; CAMARGO, Gabriel; REIS, Sabrina; BRUSCHINI, Homero; SROUGI, Miguel; LEITE, Katia; GOMES, Cristiano- Assessment of the lower urinary tract symptoms after robotic-assisted radical prostatectomy: the behavior of voiding, storage and post micturition symptoms.(2020) DA-CRUZ, JOSE ARNALDO SHIOMI; FARIA, SABRINA THALITA DOS REIS; FARIA, LEANDRO FREITAS; PONTES-JUNIOR, JOSÉ; SROUGI, MIGUEL; NAHAS, WILLIAM CARLOS; PASSEROTTI, CARLO CARMARGOABSTRACT Introduction: despite being infrequent, urinary incontinence has a huge impact on the quality of life of patients undergoing radical prostatectomy, even with the robotic-assisted technique. Objective: to assess the evolution of urinary symptoms from preoperative to 12 months after robotic-assisted radical prostatectomy. Methods: data was collected from 998 patients who underwent robotic-assisted radical prostatectomy. Demographic data, preoperative and postoperative information on patients were documented. The ICIQ and IPSS questionnaires were also applied preoperatively and after 1, 3, 6 and 12 months after the operation. Results: Out of 998 patients, 257 correctly completed all questionnaires. The mean age of the patients was 60 ± 0.74 years. We found that the total IPSS increased initially and at 6 months after the operation, it was already lower than the initial preoperative value (7.76 at 6 months vs. 9.90 preoperative, p <0.001), being that questions regarding voiding symptoms were the first to improve followed by the questions regarding post micturition and storage symptoms. As for the ICIQ variables, there was an increase with radical prostatectomy and none of them returned to the preoperative level (p<0.001). Conclusions: robotic assisted radical prostatectomy causes, at first, a worsening of urinary symptoms in the lower tract with subsequent recovery. Recovery begins with voiding symptoms, followed by post micturition and storage symptoms. The symptoms assessed by the IPSS evolve to better parameters even than those of the preoperative period, while the symptoms of incontinence assessed by the ICIQ do not reach the preoperative levels in the studied interval.